Cytogen Inc (217330) - Net Assets
Based on the latest financial reports, Cytogen Inc (217330) has net assets worth ₩35.99 Billion KRW (≈ $24.39 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩62.24 Billion ≈ $42.18 Million USD) and total liabilities (₩26.25 Billion ≈ $17.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 217330 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩35.99 Billion |
| % of Total Assets | 57.83% |
| Annual Growth Rate | 47.93% |
| 5-Year Change | 56.43% |
| 10-Year Change | 7469.3% |
| Growth Volatility | 350.54 |
Cytogen Inc - Net Assets Trend (2014–2025)
This chart illustrates how Cytogen Inc's net assets have evolved over time, based on quarterly financial data. Also explore Cytogen Inc (217330) total assets for the complete picture of this company's asset base.
Annual Net Assets for Cytogen Inc (2014–2025)
The table below shows the annual net assets of Cytogen Inc from 2014 to 2025. For live valuation and market cap data, see Cytogen Inc (217330) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩35.99 Billion ≈ $24.39 Million |
-25.92% |
| 2024-12-31 | ₩48.58 Billion ≈ $32.92 Million |
-8.94% |
| 2023-12-31 | ₩53.36 Billion ≈ $36.16 Million |
+843.31% |
| 2022-12-31 | ₩5.66 Billion ≈ $3.83 Million |
-75.42% |
| 2021-12-31 | ₩23.01 Billion ≈ $15.59 Million |
+25.48% |
| 2020-12-31 | ₩18.34 Billion ≈ $12.43 Million |
+2.33% |
| 2019-12-31 | ₩17.92 Billion ≈ $12.14 Million |
-18.70% |
| 2018-12-31 | ₩22.04 Billion ≈ $14.94 Million |
+365.76% |
| 2017-12-31 | ₩4.73 Billion ≈ $3.21 Million |
+895.21% |
| 2016-12-31 | ₩475.51 Million ≈ $322.25K |
-82.13% |
| 2015-12-31 | ₩2.66 Billion ≈ $1.80 Million |
+449.23% |
| 2014-12-31 | ₩484.59 Million ≈ $328.40K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Cytogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9507875538000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩133.09 Billion | 374.26% |
| Total Equity | ₩35.56 Billion | 100.00% |
Cytogen Inc Competitors by Market Cap
The table below lists competitors of Cytogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Raisio Oyj
HE:RAIKV
|
$92.27 Million |
|
Hainan Airlines Co Ltd B
SHG:900945
|
$92.36 Million |
|
Y-Entec Co. Ltd
KQ:067900
|
$92.38 Million |
|
Intech Biopharm Ltd
TWO:6461
|
$92.41 Million |
|
EPE Capital Partners Ltd
JSE:EPE
|
$92.24 Million |
|
Lion Selection Group Ltd
AU:LSX
|
$92.23 Million |
|
Cameo Communications Inc
TW:6142
|
$92.23 Million |
|
ÖKOWORLD AG
XETRA:VVV3
|
$92.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cytogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,583,191,260 to 35,562,320,010, a change of -13,020,871,250 (-26.8%).
- Net loss of 12,342,882,560 reduced equity.
- Other factors decreased equity by 677,988,690.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-12.34 Billion | -34.71% |
| Other Changes | ₩-677.99 Million | -1.91% |
| Total Change | ₩- | -26.80% |
Book Value vs Market Value Analysis
This analysis compares Cytogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 47.84x to 3.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩123.32 | ₩5900.00 | x |
| 2017-12-31 | ₩1076.05 | ₩5900.00 | x |
| 2018-12-31 | ₩3912.31 | ₩5900.00 | x |
| 2019-12-31 | ₩3180.77 | ₩5900.00 | x |
| 2020-12-31 | ₩3254.77 | ₩5900.00 | x |
| 2021-12-31 | ₩1314.62 | ₩5900.00 | x |
| 2022-12-31 | ₩317.61 | ₩5900.00 | x |
| 2023-12-31 | ₩2408.36 | ₩5900.00 | x |
| 2024-12-31 | ₩2105.94 | ₩5900.00 | x |
| 2025-12-31 | ₩1541.53 | ₩5900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cytogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -47.37%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 1.75x
- Recent ROE (-34.71%) is above the historical average (-122.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -283.35% | -381.75% | 0.18x | 4.24x | ₩-1.42 Billion |
| 2015 | -143.13% | -777.99% | 0.12x | 1.60x | ₩-4.08 Billion |
| 2016 | -451.97% | -252.89% | 0.17x | 10.64x | ₩-2.20 Billion |
| 2017 | -55.37% | -1272.69% | 0.04x | 1.20x | ₩-3.09 Billion |
| 2018 | -11.79% | -212.09% | 0.05x | 1.03x | ₩-4.80 Billion |
| 2019 | -23.11% | -518.30% | 0.04x | 1.10x | ₩-5.93 Billion |
| 2020 | -26.66% | -760.70% | 0.02x | 1.54x | ₩-6.72 Billion |
| 2021 | -47.25% | -3125.13% | 0.01x | 2.41x | ₩-13.17 Billion |
| 2022 | -331.87% | -2467.37% | 0.02x | 7.29x | ₩-19.34 Billion |
| 2023 | -29.56% | -495.22% | 0.04x | 1.40x | ₩-21.11 Billion |
| 2024 | -35.23% | -156.88% | 0.15x | 1.49x | ₩-21.98 Billion |
| 2025 | -34.71% | -47.37% | 0.42x | 1.75x | ₩-15.90 Billion |
Industry Comparison
This section compares Cytogen Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $106,126,600,864
- Average return on equity (ROE) among peers: -13.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cytogen Inc (217330) | ₩35.99 Billion | -283.35% | 0.73x | $92.24 Million |
| NSN Co. Ltd (031860) | $102.59 Billion | 0.00% | 0.91x | $8.50 Million |
| JOONGANG DNM Co.Ltd (051980) | $12.34 Billion | -28.88% | 0.57x | $144.40 Million |
| GeneMatrix Inc (109820) | $23.15 Billion | -3.87% | 0.35x | $27.26 Million |
| Genoray Co. Ltd (122310) | $66.53 Billion | 15.29% | 0.29x | $38.45 Million |
| Green Cross Lab Cell Corporation (144510) | $48.10 Billion | 4.84% | 0.13x | $241.86 Million |
| Optipharm.CO.LTD (153710) | $13.50 Billion | -2.58% | 0.52x | $51.60 Million |
| Gencurix Inc (229000) | $30.99 Billion | -111.87% | 0.78x | $25.56 Million |
| P&K Skin Research Center Co. Ltd (347740) | $70.81 Billion | 10.07% | 0.05x | $48.83 Million |
| Access Bio Inc (950130) | $587.14 Billion | 0.00% | 0.18x | $125.38 Million |
About Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more